Scholarlink

<p>Diabetic retinopathy (DR) is the major cause of vision decline in adults worldwide. Photoreceptor loss is considered a main pathogenesis of retinal dysfunction in DR. Recently, mesenchymal stem cell-derived extracellular vesicles (MEVs) treatment has been considered a promising cell-free approach for retinal disorders. However, the role and mechanism of MEVs in alleviating photoreceptor injury in DR remain unclear. In this study, MEV treatment improved retinal function and inhibited photoreceptor apoptosis in db/db mice. Mechanistically, the deubiquitinating enzyme ubiquitin-specific peptidase 25 (USP25) in MEVs was responsible for the MEV-mediated photoreceptor therapy by inhibiting hyperglycemia-induced αA-crystallin (CRYAA) ubiquitination. Moreover, USP25-enriched MEVs modified with the photoreceptor-targeting peptide MH42 (MEVs<sup>MH42</sup>-USP25) were prepared by genetic engineering and surface conjugation. MEVs<sup>MH42</sup>-USP25 exhibited elevated repairing efficiency to attenuate retinal dysfunction and photoreceptor loss in db/db mice. Our study develops an MEV-based nanocarrier for photoreceptor-targeted delivery and highlights the effectiveness of MEVs<sup>MH42</sup>-USP25 as novel therapeutics for DR.</p> Graphical abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Engineered MEVs for photoreceptor-targeted delivery of USP25 to alleviate diabetic retinopathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月20日

查看全文
  • Yaoxiang Sun,
  • Shenyuan Chen,
  • Xiaoyuan Qi,
  • Yuntong Sun,
  • Zhengmei Jiang,
  • Jie Chang,
  • Yongjun Ma,
  • Jin Huang,
  • Benshuai You,
  • Fengtian Sun

摘要

Diabetic retinopathy (DR) is the major cause of vision decline in adults worldwide. Photoreceptor loss is considered a main pathogenesis of retinal dysfunction in DR. Recently, mesenchymal stem cell-derived extracellular vesicles (MEVs) treatment has been considered a promising cell-free approach for retinal disorders. However, the role and mechanism of MEVs in alleviating photoreceptor injury in DR remain unclear. In this study, MEV treatment improved retinal function and inhibited photoreceptor apoptosis in db/db mice. Mechanistically, the deubiquitinating enzyme ubiquitin-specific peptidase 25 (USP25) in MEVs was responsible for the MEV-mediated photoreceptor therapy by inhibiting hyperglycemia-induced αA-crystallin (CRYAA) ubiquitination. Moreover, USP25-enriched MEVs modified with the photoreceptor-targeting peptide MH42 (MEVsMH42-USP25) were prepared by genetic engineering and surface conjugation. MEVsMH42-USP25 exhibited elevated repairing efficiency to attenuate retinal dysfunction and photoreceptor loss in db/db mice. Our study develops an MEV-based nanocarrier for photoreceptor-targeted delivery and highlights the effectiveness of MEVsMH42-USP25 as novel therapeutics for DR.

Graphical abstract